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BACKGROUND: Profound loss of adipose tissue is a hallmark of cancer cachexia. Zinc-a2-glycoprotein (ZAG), a recently identified
adipokine, is suggested as a candidate in lipid catabolism.
METHODS: In the first study, eight weight-stable and 17 cachectic cancer patients (weight loss X5% in previous 6 months) were
recruited. Zinc-a2-glycoprotein mRNA and protein expression were assessed in subcutaneous adipose tissue (SAT), subcutaneous
adipose tissue morphology was examined and serum ZAG concentrations were quantified. In the second cohort, ZAG release by
SAT was determined in 18 weight-stable and 15 cachectic cancer patients. The effect of ZAG on lipolysis was evaluated in vitro.
RESULTS: Subcutaneous adipose tissue remodelling in cancer cachexia was evident through shrunken adipocytes with increased fibrosis.
In cachectic cancer patients, ZAG mRNA was upregulated (2.7-fold, P¼0.028) while leptin mRNA decreased (2.2-fold, P¼0.018);
serum ZAG levels were found to be unaffected. Zinc-a2-glycoprotein mRNA correlated positively with weight loss (r¼0.51,
P¼0.01) and serum glycerol levels (r¼0.57, P¼0.003). Zinc-a2-glycoprotein release by SAT was also elevated in cachectic patients
(1.5-fold, P¼0.024) and correlated with weight loss (r¼0.50, P¼0.003). Recombinant ZAG stimulated lipolysis in human
adipocytes.
CONCLUSIONS: Zinc-a2-glycoprotein expression and secretion by adipose tissue is enhanced in cachectic cancer patients. Given its
lipid-mobilising effect, ZAG may contribute to adipose atrophy associated with cancer cachexia in human beings.
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Cachexia, a catabolic syndrome manifested by profound loss of
adipose tissue and skeletal muscle, affects most cancer patients
(Fearon et al, 2006). Progressive cachexia has a detrimental effect
on antitumour treatment and is associated with reduced survival
(Dewys et al, 1980). Muscle wasting has been the focus of intensive
research, with the demonstration of reduced protein synthesis and
increased proteolysis in rodent models of cachexia and in cachectic
cancer patients (Tisdale, 2005; Argiles et al, 2006). Fat loss occurs
more rapidly than the reduction of lean mass in cancer cachexia
(Fouladiun et al, 2005), with the most rapid loss of adipose tissue
within 3 months of death (Lieffers et al, 2009). Although extensive
depletion of body fat has been considered as a hallmark of cancer
cachexia, the underlying molecular basis is poorly understood.
A better knowledge of the mechanisms involved in adipose
atrophy is crucial for the development of effective treatments for
the syndrome.
Several factors derived from tumours and/or host tissues are
implicated in fat depletion during progressive cachexia (Tisdale,
2005). These factors include inflammatory cytokines such as
tumour necrosis factor a (TNFa) and lipolytic factors such as
zinc-a2-glycoprotein (ZAG). Zinc-a2-glycoprotein, a secreted solu-
ble protein, was initially isolated from human plasma (Burgi and
Schmid, 1961), and subsequently found in various tissues (Tada
et al, 1991). Zinc-a2-glycoprotein is overexpressed by several types
of malignant tumour, such as breast, prostate and lung cancers
(Diez-Itza et al, 1993; Hale et al, 2001; Albertus et al,2 0 0 8 ) ,a n di t
has been proposed as a cancer biomarker. The physiological
functions of ZAG remain to be established, but the protein has been
implicated in hindering cell proliferation (He et al, 2001; Schmitt
et al, 2008) and modulating melanin production (Hale, 2002).
The most studied property of ZAG is its involvement in lipid
metabolism (Bing and Trayhurn, 2009). Zinc-a2-glycoprotein has
been shown to be identical to a lipid-mobilising factor (LMF)
purified from the urine of patients with cancer cachexia (Todorov
et al, 1998). Treatment with purified ZAG can induce selective
reduction in body fat in both genetically obese (ob/ob) mice and
outbred NMRI mice (Hirai et al, 1998; Bing et al, 2002). In vitro,
ZAG stimulates lipolysis in isolated murine and human adipocytes,
and this has been postulated to be mediated by the
b3-adrenoceptor in rodents (Hirai et al, 1998). There is also
evidence that ZAG promotes lipid utilisation through the upregula-
tion of uncoupling protein-1 in brown fat (Bing et al, 2002) and
increasing overall fatty acid oxidation (Russell and Tisdale, 2010).
Adipose tissue plays important roles in energy homeostasis
and metabolism through secreted adipokines (Trayhurn and
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sBing, 2006). The fat-lowering effect of ZAG and the secretory
function of adipose tissue led to the hypothesis that ZAG could be
produced by adipose tissue, thereby influencing adipocyte
metabolism (Bing et al, 2004). Indeed, our previous work has
shown that the ZAG gene and protein is expressed in the major fat
depots of mice and human beings (Bing et al, 2004). Subsequently,
ZAG was shown to be secreted by differentiated human adipocytes
(Bao et al, 2005) at levels comparable with adiponectin, one of the
most abundant proteins in adipose tissue (Mracek et al, 2010a);
ZAG, therefore, is a major adipokine. Recent evidence suggests
that adipose tissue-derived ZAG is inversely linked to adiposity.
Zinc-a2-glycoprotein gene and protein expression in adipose
tissue is downregulated in obese ob/ob mice (Mracek et al,
2010b) and in obese human subjects (Selva et al, 2009). In contrast,
ZAG mRNA and protein levels are substantially increased in
adipose tissue of tumour-bearing mice with profound
fat loss, suggesting a role for ZAG in adipose tissue catabolism
(Bing et al, 2004).
Despite this knowledge, the clinical relevance of ZAG in human
cancer cachexia is still not known. In this study, we investigated
the potential role of adipokine ZAG in the pathogenesis of cancer
cachexia in human beings. Zinc-a2-glycoprotein expression and
secretion by adipose tissue (subcutaneous) was examined along
with serum ZAG levels in cancer patients with cachexia as
compared with weight-stable controls. We also analysed the
relationship between adipokine ZAG (expression and release)
and the extent of weight loss in cancer patients. Finally, the effect
of recombinant ZAG protein on lipid mobilisation in human
adipocytes was assessed.
MATERIALS AND METHODS
Patients and sample collection
Twenty-five cancer patients (upper gastrointestinal, n¼12;
pancreatic, n¼13) were recruited at the Department of Clinical
and Surgical Sciences, University of Edinburgh. Patients did not
receive previous anticancer therapy and underwent potentially
curative abdominal surgery. The weight and height of the subjects
were measured, and body mass index (BMI) and total fat mass
were calculated (Moses et al, 2001). Mid-arm muscle circumfer-
ence (MAMC) was calculated from triceps skin-fold thickness
(TSF) and total mid-arm circumference (MAC): MAMC¼
MAC [p TSF]. For each patient, pre-illness stable weight was
self-reported and the percentage of weight loss was calculated. The
patients were divided into cachectic (n¼17) and weight-stable
(n¼8) groups. Cachexia was defined as unintentional weight loss
X5% during the previous 6 months; weight-stable patients
were defined as patients without apparent weight change during
the previous 6 months.
Patients had fasted overnight before undergoing surgery.
A venous blood sample was taken before the surgical procedure
and centrifuged to obtain serum, which was subsequently stored at
 801C for later analysis. An open biopsy of approximately 1–2g
of abdominal subcutaneous adipose tissue (SAT) was obtained at
the start of the surgical procedure. Samples were rinsed in PBS and
snap-frozen immediately in liquid nitrogen, and then stored at
 801C until later analysis.
For the study of ZAG protein release by adipose tissue, another
cohort of 34 patients with gastrointestinal cancer (oesophagus,
n¼8; pancreas, n¼12; stomach, n¼4; gall bladder, n¼2; and
colon, n¼5) and liver metastasis with no clear primary tumour
(n¼3) were recruited at the Karolinska University Hospital,
Stockholm, Sweden. Among them, 15 patients experienced weight
loss (X5% during the previous 6 months) and 19 were weight
stable. The patients were investigated after an overnight fast.
Height and weight was determined and body composition assessed
by whole-body electrical bioimpedance (Quad Scan 4000; Bodystat,
Isle of Man, UK). Abdominal SAT (B500mg) was taken by needle
biopsy and immediately processed for measurements of in vitro
protein secretions, as described previously (Ryden et al, 2008).
Tumour stage was assessed according to the AJCC/UICC system
(Sobin, 2002). Fully informed, written consent was obtained in all
cases and the study protocol was approved by the appropriate
Regional Human Ethics Committees.
Histology
Subcutaneous adipose tissue biopsies from cachexia and weight-
stable cancer patients were fixed in 10% neutral formalin for 24h,
dehydrated in absolute ethanol, cleared in xylene and then
embedded in paraffin. The paraffin was cut into 5-mm sections
that were stained with Harris haematoxylin, counterstained with
eosin, and then evaluated and photographed under light micro-
scopy. To detect the collagen-fibre content in SAT, sections were
stained with Sirius Red (Bing et al, 2006).
RNA extraction and real-time PCR
Total RNA was extracted from tissues or cells using Trizol
(Invitrogen, Carlsbad, CA, USA). First-strand cDNA was reverse
transcribed from 0.5mg of total RNA using an iScript first-strand
synthesis kit (BioRad, Hercules, CA, USA) in a final volume of
10ml. Real-time PCR amplification was performed in a final
volume of 12.5ml, containing cDNA (equivalent to 10ng of RNA),
primers, TaqMan probe FAM-TAMRA and a master mix made
from qPCR core kit (Eurogentec, Seraing, Belgium) using a
Stratagene Mx3005P instrument. The sequence of primers and
probe for human ZAG, leptin and b-actin were as described
previously (Bing et al, 2004; Bao et al, 2005). Polymerase chain
reaction cycling conditions were: 951C for 10min, followed by 40
cycles (951C for 15s, 601C for 1min). Samples were normalised to
b-actin and the results expressed as fold changes of Ct value
relative to controls using the 2
 DDCt formula.
Measurement of SAT ZAG protein
For quantification of ZAG protein levels, SAT samples were
homogenised using glass/glass homogenisers in buffer consisting
of 250mM sucrose, 10mM Tris-HCl (pH 7.4), 1mM EDTA and
protease inhibitor cocktail (dilution 1:500; Sigma, Poole, Dorset,
UK). Homogenates were spun down at 12000g for 10min at 41C
and upper fat layer was discarded. Infranatant and sediment were
rehomogenised by pipetting up and down before being used for
assay. The total protein content of the homogenates was
determined by the BCA protein assay reagent (Sigma). Zinc-a2-
glycoprotein protein content in tissue homogenates was measured
with an enzyme-linked immunosorbent assay (ELISA) kit
(BioVendor, Rosice, Czech Republic) according to the manufac-
turer’s protocol. Zinc-a2-glycoprotein protein levels were
normalised to total protein content.
Measurement of SAT ZAG secretion
Subcutaneous adipose tissue explants were incubated as described
previously (Ryden et al, 2008). In brief, adipose tissue (about
300mg) was incubated in 3ml of medium for 2h at 371C. The
incubation medium was then collected from each sample and
centrifuged at 1000r.p.m. for 10min to remove cell debris and the
supernatant was stored at  801C until analysis. The tissue was
collected and subjected to lipid extraction. Zinc-a2-glycoprotein
secretion by adipose tissue was determined as the protein
concentration in the medium using an ELISA kit (BioVendor,
Rosice, Czech Republic) and related to the lipid weight of the
incubated tissue.
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sSerum analyses
Serum ZAG levels were measured using an ELISA kit (BioVendor).
Serum leptin levels were also evaluated by ELISA (R&D Systems,
Abingdon, UK). The concentrations of serum albumin and lipids
were determined by standard methods employed by the clinical
chemistry laboratories.
Culture of adipocytes
SGBS (Simpson–Golabi–Behmel syndrome) cells, kindly provided
by Professor M Wabitsch, were maintained and cultured as
described previously (Bao et al, 2005). In brief, cells were cultured at
371C in a humidified atmosphere of 5% CO2/95% air. SGBS
preadipocytes were maintained in DMEM/Ham’s F12 (1:1) medium
(Invitrogen, Paisley, UK) containing 10% (vv
 1)f o e t a lc a l fs e r u m
(FCS; Sigma) and antibiotics (penicillin/streptomycin; Lonza,
Twekesbury, UK). Preadipocytes were seeded onto 12-well plates
and grown until confluence. At confluence, cells were induced to
differentiate (day 0) by incubation for 5 days in FCS free medium
containing 0.25mM dexamethasone, 500mM 3-isobutyl-1-methyl-
xanthine, 10nM insulin, 200pM triiodothyronine (T3), 1mM cortisol
(all from Sigma) and 2mM rosiglitazone (GlaxoSmithKline, Uxbridge,
UK). Cells were then maintained in feeding medium (containing
10nM insulin, 1mM cortisol and 200pM T3, all from Sigma) until full
differentiation, verified by observing the accumulation of lipid
droplets under the microscope.
For the study of the effect of ZAG on lipolysis, differentiated
SGBS adipocytes (day 15) were treated with 5 or 20mgml
 1
recombinant ZAG (BioVendor) for 18h. Isoproterenol (10mM)o r
IBMX (100mM) was similarly incubated with the cells as positive
references. Cells without the addition of any agents were used
as controls. At the end of incubation, the culture medium
was collected and lipolysis was determined as glycerol release into
the medium using a commercial kit (Sigma).
Statistical analysis
Differences between the two groups were analysed by Student’s
unpaired t-test for normal distributed data. Mann–Whitney test
was used for data with a non-normal distribution and data were
presented as median with 75th percentile. Non-parametrical w
2 test
was performed to compare difference of the tumour stage between
the two groups. Associations between quantitative variables were
assessed with Spearman’s rank correlation test. Statistical analyses
were performed using SPSS program, and statistical difference was
considered as significant when two-tailed Po0.05.
RESULTS
Characteristics of patients
The clinical characteristics of patients (the UK cohort and the
Swedish cohort) are presented in Table 1. There were no
significant differences in gender or age between cachectic and
weight-stable cancer patients. Cachectic patients had a lower BMI
(P¼0.0015, UK cohort), fat mass (P¼0.01–0.016, both cohorts)
and MAMC (P¼0.0082, measured only in the UK cohort), but
greater weight loss (Po0.0001, both cohorts) compared with
weight-stable patients. With respect to tumour stage, no significant
difference was found between the two groups (both cohorts).
There was no significant difference in the serum concentration
of ZAG between cachectic and weight-stable cancer patients
(55.3±10.9 vs 58.7±7.7, P¼0.45) (Table 1). Serum ZAG levels
showed no correlation with BMI (r¼0.092, P¼0.66) or weight loss
(r¼ 0.11, P¼0.61). In contrast, serum leptin levels were lower
(by 53%, P¼0.035) in cachectic patients compared with weight-
stable cancer patients (Table 1). Serum leptin also showed a
positive correlation with BMI (r¼0.61, P¼0.0018) and an inverse
correlation with weight loss (r¼ 0.53, P¼0.0098).
Adipose tissue remodelling in patients with
cancer cachexia
Examination under light microscopy showed substantial morpho-
logical alterations of SAT in cachectic cancer patients compared
with weight-stable cancer controls. The changes were characterised
by the tissue containing shrunken adipocytes and this was
paralleled by an increase in interstitial space (Figure 1A). To
Table 1 Anthropometric, biochemical and hormonal characteristics of cancer patients
UK cohort Swedish cohort
Weight stable (n¼8) Cachectic (n¼17) P-value Weight stable (n¼19) Cachectic (n¼15) P-value
Males/females (n) 7/1 8/9 0.088* 14/5 13/2 0.35
#
Age (years) 67±66 4 ±10 0.69 66±76 4 ±11 0.49
BMI (kgm
 2) 28.0±3.4 22.8±3.4 0.0015 25.7±3.5 23.3±4.2 0.072
Total fat mass (kg) 25.2±4.4 18.1±6.4 0.010 N/A
Body fat (%) 30.8±3.7 27.1±4.8 0.060 27.3±3.7 21.7±8.4 0.0016
MAMC (cm) 26.5±2.9 23.2±2.4 0.0082 N/A
Weight loss (%) 0.3 (0.7) 11.8 (16.8) o0.0001
w 1.2±2.7 13.3±6.3 o0.0001
Tumour stage
1 3 3 0.26
# 2 1 0.28
#
20 6 0 0
32 3 8 1 1
42 3 8 3
Albumin (gl
 1) 36.9±3.9 32.7±5.4 0.064 37.9±2.6 34.0±3.7 0.0017
Triglycerides (mmoll
 1) 1.28±0.74 1.26±1.04 0.96 1.20±0.35 1.08±0.42 0.37
Cholesterol (mmoll
 1) 4.94±1.92 4.01±1.30 0.16 4.85±1.09 4.47±1.16 0.35
Glycerol (mgml
 1) 0.44±0.25 0.64±0.37 0.19 N/A
Total fat mass (kg)
Serum ZAG (mgml
 1) 58.7±7.7 55.3±10.9 0.45 N/A
Serum leptin (ngml
 1) 13.7±6.0 6.6±7.3 0.035 N/A
Abbreviations: BMI¼body mass index; MAMC¼mid-arm muscle circumference; N/A¼not applicable; ZAG¼Zinc-a2-glycoprotein. Tumour stage was not available on one
weight-stable patient from the Swedish cohort. Values are means±s.d. or median (75th percentile). They were compared by either an unpaired Student’s t-test, w
2 test (
#),
Mann–Whitney test (
w) or Fisher’s exact test (*).
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sfurther examine the nature of the extracellular matrix, sections of
SAT were stained with Sirius Red. There was a strong Sirius Red
staining in the stroma of adipose tissue from cachectic patients,
which indicates a substantial increase in collagen-fibre content in
the tissue (Figure 1B).
ZAG expression in SAT is upregulated in cachectic
cancer patients
Subcutaneous adipose tissue ZAG mRNA levels were significantly
higher in cachectic cancer patients than in weight-stable cancer
patients (2.7-fold, P¼0.028) (Figure 2A). In contrast, mRNA levels
of leptin, known as an indicator of adiposity and here used as a
reference gene for ZAG, were significantly reduced in cachectic
patients (2.2-fold, P¼0.018) (Figure 2B). Further analysis of ZAG
protein expression in SAT showed an increase in cachectic patients
compared with weight-stable cancer patients, but this was
not statistically significant (1.4-fold, P¼0.076) (Figure 2C).
In addition, ZAG protein levels exhibited a positive correlation
with ZAG mRNA levels in SAT (r¼0.42, P¼0.04) (Figure 2D).
ZAG expression in SAT is associated with weight loss
To further investigate whether adipokine ZAG has a potential role
in the pathogenesis of cancer cachexia in human beings, the
relationship between SAT ZAG mRNA levels and several aspects of
nutritional status were analysed. As shown in Figure 3A, ZAG
mRNA levels correlated negatively with BMI (r¼ 0.50, P¼0.01).
In contrast, ZAG mRNA showed a positive correlation with weight
loss (r¼0.51, P¼0.01) (Figure 3B). Furthermore, analysis of the
potential link between adipokine ZAG and lipolysis revealed that
ZAG mRNA levels correlated positively with serum glycerol levels
(r¼0.57, P¼0.003) (Figure 3C). In addition, SAT ZAG protein
levels also showed an inverse relationship with BMI (r¼ 0.41,
50 m 50 m
40 m 40 m
Cachectic Weight stable
Figure 1 Morphological characteristics of adipose tissue in cachexia. Representative sections of subcutaneous adipose tissue from weight-stable and
cachectic cancer patients stained with haematoxylin–eosin (A) or Sirius Red (B).
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Figure 2 Zinc-a2-glycoprotein gene and protein expression in adipose
tissue of cancer patients. mRNA levels of ZAG (A) and leptin (B)i n
subcutaneous adipose tissue of weight-stable (n¼8) and cachectic (n¼17)
cancer patients by real-time PCR, expressed as means±s.e.m. Zinc-a2-
glycoprotein protein levels in subcutaneous fat of weight-stable (n¼8) and
cachectic (n¼17) cancer patients by ELISA, expressed as means±s.e.m.
(C) Correlation between ZAG protein and mRNA levels (D) in adipose
tissue; n¼25. *Po0.05 compared with weight-stable patients.
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sP¼0.045) and positive correlation with weight loss (r¼0.41,
P¼0.04).
Contrary to the results of ZAG, leptin mRNA level showed a
positive correlation with BMI (r¼0.65, Po0.001) (Figure 3D), but
were negatively correlated with weight loss (r¼ 0.50, P¼0.01)
(Figure 3E).
ZAG protein secretion from SAT is elevated in
cachectic cancer patients
As there is enhanced ZAG expression in SAT in cancer cachexia,
we investigated whether there is an increase in ZAG protein release
from the tissue. Zinc-a2-glycoprotein was secreted by the SAT
explants at levels of about 10–210ng per g lipid per 2h. In line
with the results of ZAG expression, a 50% increase in ZAG protein
secretion by adipose tissue was found in cachectic cancer patients
when compared with weight-stable cancer patients (P¼0.024)
(Figure 4A). Furthermore, there was a positive correlation between
ZAG protein secretion and weight loss in cancer patients (r¼0.50,
P¼0.003) (Figure 4B).
Treatment with ZAG stimulates glycerol release by
human adipocytes
In light of the upregulation of ZAG expression and secretion by
adipose tissue in cancer cachexia, we investigated whether ZAG
has a local effect through lipid mobilisation in human adipose
tissue. Differentiated human adipocytes (SGBS) were treated
with recombinant ZAG and the effect on lipolysis was examined.
As shown in Figure 5, glycerol release by SGBS adipocytes was
induced with a 43-fold increase at both the lower (5mgml
 1) and
higher (20mgml
 1) doses of ZAG treatment, and the increase
was statistically significant at the dose of 5mgml
 1 (Po0.01).
As positive controls, treatment with isoproterenol and IBMX led to
a six- and five-fold increase in glycerol release, respectively (both
Po0.01) (Figure 5).
DISCUSSION
This study shows profound changes in SAT morphology in
patients with cancer cachexia. Adipose tissue atrophy is char-
acterised by a reduction in adipocyte cell size, and this is
accompanied by a significant increase in tissue matrix fibrosis.
Similar alterations in adipose tissue structure have been observed
in our previous study in cancer-bearing mice (Bing et al, 2006).
In agreement with these changes in adipose tissue morphology,
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sa decrease in fat cell volume without change in total fat
cell number has been recently reported in cachectic patients
with gastrointestinal cancer (Agustsson et al, 2007; Ryden et al,
2008). These results provide evidence that adipose tissue
remodelling with reduced lipid storage occurs in human
cancer cachexia.
Until now, there has been no information available on ZAG
production in cancer cachexia in human subjects. The results of
this study show that the expression levels of ZAG transcripts and
protein in SAT were upregulated in cachectic cancer patients
compared with weight-stable cancer patients. The enhanced
adipose tissue ZAG expression in cancer cachexia suggests that
ZAG could be a local catabolic mediator within the tissue. Further
analyses show that ZAG expression in SAT was linked to adiposity
and weight loss in cancer patients. We show that ZAG mRNA levels
exhibited an inverse relationship with BMI, but a positive
correlation with weight loss. In parallel, ZAG protein content in
adipose tissue correlated negatively with BMI, but positively with
weight loss. Similarly, a negative association between adipose
tissue ZAG expression and BMI has been reported in studies of
obese human subjects (Selva et al, 2009; Mracek et al, 2010a).
These observations indicate a contributory role for ZAG in the
modulation of body adiposity (Bing et al, 2010). In this study,
however, no significant differences in serum ZAG levels were
found between cachectic and weight-stable cancer patients. Other
data on circulating ZAG levels in relation to human obesity are
inconsistent, being reported as either decreased (Ceperuelo-
Mallafre et al, 2009; Selva et al, 2009) or increased (Yeung et al,
2009). Circulating levels of ZAG could be influenced by its
production in other tissues such as the liver, a major site for ZAG
production (Tada et al, 1991). Although ZAG mRNA levels were
lowered in ob/ob mice (Mracek et al, 2010b) and obese patients
(Selva et al, 2009), the extent of ZAG production by the liver
in human cancer cachexia is not known and further studies are
warranted. In addition, ZAG is known to be overexpressed by
malignant tumours and this may over-ride the contribution of
ZAG produced by adipose tissue to the circulating pool. Therefore,
it is likely that adipose tissue-derived ZAG is more important
locally through an autocrine/paracrine action.
In marked contrast to the results of ZAG, SAT leptin mRNA,
which increases with fat mass accretion, is decreased in cachectic
cancer patients. Furthermore, circulating leptin levels are also
reduced in these patients. Leptin as a key adipokine is known to be
an indicator of body adiposity (Kettaneh et al, 2007). The
downregulation of leptin production in cachectic cancer patients
is in agreement with a fall of adiposity in cancer cachexia.
Another key finding of this study is the demonstration that
human adipose tissue secretes ZAG protein, and more importantly,
the levels of ZAG secretion are higher in cachectic than in weight-
stable cancer patients. Local secretion of ZAG from adipose tissue
in cachexia has not been described previously. This study is the
first to show upregulated production of the adipokine, suggesting
that it plays a key autocrine/paracrine role in the cachexia-
associated tissue atrophy. Importantly, further analyses reveal a
positive relationship between ZAG protein release and weight loss
in cancer patients. The elevation in ZAG production with increased
severity of cachexia further supports a role for ZAG in catabolising
body fat in human beings.
Although the molecular mechanisms of fat loss in cachexia
remain to be established, increased lipolysis is considered to be a
key factor. It has been shown that whole-body lipolysis, measured
by the rate of appearance of glycerol, is higher in patients with
cancer who are losing weight than in healthy subjects (Zuijdgeest-
van Leeuwen et al, 2000). A recent study has shown that lipolytic
activity (fasting plasma glycerol or fatty acids) is higher in cancer
cachexia patients than in weight-stable controls (Agustsson et al,
2007). Furthermore, increased expression of hormone-sensitive
lipase, a rate-limiting enzyme of the lipolytic pathway, has been
reported in adipose tissue of patients with cancer cachexia
(Thompson et al, 1993; Agustsson et al, 2007). In vitro, using
mature adipocytes isolated from SAT, the lipolytic effects of
catecholamines and natriuretic peptide were increased by 42-fold
in cancer patients with cachexia compared with weight-stable
cancer patients, although basal lipolysis was unaffected (Agustsson
et al, 2007). In this study, we show a positive correlation between
ZAG expression in adipose tissue and fasting serum glycerol levels,
suggesting an involvement of ZAG in lipolytic activity.
The proposed role for ZAG in lipid mobilisation has primarily
been based on studies in rodents and murine adipocytes (Hirai
et al, 1998). Recent work has shown that ZAG-deficient mice are
susceptible to weight gain when fed a high-fat diet, which appears
to be the result of a decreased lipolytic response to adrenergic
stimuli in white adipocytes, although basal lipolysis is not affected
(Rolli et al, 2007). In ZAG-overexpressing transgenic mice, which
exhibit decreased body weight and epididymal fat, mRNA levels of
HSL in adipose tissue are elevated and the tissue is sensitised to the
action of catecholamines (Gong et al, 2009). However, it is unclear
whether this is the case in human beings with increased ZAG.
We have shown that ZAG production (both expression and
release) by SAT is increased in cachectic cancer patients,
supporting a role for ZAG in human beings. Considering its
action as a LMF in rodents, it is essential to examine further if ZAG
acts as a catabolic mediator through its lipolytic effect in human
adipose tissue. This study reveals that recombinant ZAG, at
physiologically relevant concentrations, increases glycerol release
from differentiated human adipocytes. Our finding suggests that
ZAG could stimulate lipolysis in human adipose tissue, and
therefore contribute to increased lipid mobilisation in human
cancer cachexia. This result also provides the potential for novel
therapeutic strategies against ZAG. The crystal structure of ZAG
has been shown to have a high degree of similarity to the major
histocompatibility complex class I molecules (Sanchez et al, 1999).
As the hydrophobic groove formed by the a1–a2 domain of ZAG
molecule may be important in lipid metabolism (McDermott et al,
2006; Hassan et al, 2008), further studies are warranted to assess
whether blocking of this binding site and/or local ZAG production
can be used for preventing the loss of adipose tissue in malignancy.
On the other hand, ZAG might be employed for the treatment
of visceral obesity as it stimulates lipolysis via b3-adrenoceptors
(Russell et al, 2004) and b3-adrenoceptor sensitivity is enhanced in
response to noradrenaline in visceral fat of obese subjects
(Lo ¨nnqvist et al, 1995).
In conclusion, this study shows that in human subjects, ZAG
expression and its protein secretion by SAT are enhanced in cancer
cachexia irrespective of tumour stage. This upregulation of adipose
tissue-derived ZAG is associated with the severity of cachexia.
However, circulating ZAG levels do not differ between cachectic
and weight-stable cancer patients. Finally, recombinant ZAG
stimulates glycerol release from human adipocytes. Overall, our
results suggest that adipokine ZAG plays a key role in the
pathogenesis of cancer cachexia in human beings, at least in part,
through its lipid mobilising action in adipose tissue.
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